第十一届董事会第十七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 证券代码:000623 证券简称:吉林敖东 公告编号:2025-024 吉林敖东药业集团股份有限公司 一、董事会会议召开情况 1．吉林敖东药业集团股份有限公司（以下简称"公司"）第十一届董事会 第十七次会议通知以书面方式于2025年4月18日发出。 2．会议于2025年4月29日在公司六楼会议室以现场方式召开。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券 报》《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《公司2025年 第一季度报告》（公告编号：2025-025）。 2．审议《关于聘任王超先生为公司副总经理的议案》 表决结果：通过。同意票9票，反对票0票，弃权票0票。 全文详见公司于2025年4月30日在《证券时报》《中国证券报》《上海证券报》 《证券日报》及巨潮资讯网http://www.cninfo.com.cn披露的《关于聘任公司副 3．本次会议应到会董事9名，实际参加会议现场表决董事9名。 4．会议由公司董 ...

吉林敖东：一季度归母净利润5.17亿元，同比增长259.75% 金十数据4月29日讯，吉林敖东公告，2025年第一季度实现营业收入6.23亿元，同比下降27.71%；归属 于上市公司股东的净利润5.17亿元，同比增长259.75%；基本每股收益0.4396元。 ...

Revenue and Profit - The company's revenue for Q1 2025 was ¥622,624,001.54, a decrease of 27.71% compared to ¥861,336,047.60 in the same period last year[4] - Net profit attributable to shareholders increased by 259.75% to ¥516,839,939.37 from ¥143,665,579.44 year-on-year[4] - Basic and diluted earnings per share rose by 244.24% to ¥0.4396 from ¥0.1277 in the same period last year[4] - Net profit for the current period is ¥516,513,643.37, compared to ¥132,653,063.68 in the previous period, representing a significant increase[19] - Earnings per share (EPS) for the current period is ¥0.4396, up from ¥0.1277 in the previous period[19] Cash Flow - The net cash flow from operating activities improved significantly, reaching ¥55,946,098.42, a 538.76% increase from -¥12,751,058.81 in the previous year[4] - Net cash flow from operating activities was $55,946,098.42, a significant improvement compared to a negative cash flow of $12,751,058.81 in the previous period[21] - Cash inflow from investment activities totaled $714,385,824.50, up from $125,583,727.14 in the prior period[21] - Net cash flow from investment activities was negative at -$57,839,340.16, compared to -$88,593,367.85 previously[21] - Cash inflow from financing activities amounted to $680,165,022.64, a decrease from $1,740,458,808.05 in the last period[22] - Net cash flow from financing activities was -$39,769,994.80, contrasting with a positive flow of $13,396,454.21 in the previous period[22] - The ending balance of cash and cash equivalents was $1,064,016,449.93, down from $1,631,979,783.39 at the end of the previous period[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥33,511,130,541.92, reflecting a 1.54% increase from ¥33,001,896,399.52 at the end of the previous year[4] - Total assets amount to ¥33,511,130,541.92, an increase from ¥33,001,896,399.52 in the previous period[17] - Total liabilities are ¥3,830,632,233.59, compared to ¥3,719,663,017.59 in the previous period, reflecting a rise[17] - The company’s goodwill and intangible assets are reported at ¥466,307,167.58, up from ¥437,315,884.41 in the previous period[16] Investment and Income - The company's investment income surged by 90.00% to ¥507,603,747.81 compared to ¥267,154,606.73 in the previous year[9] - The fair value change income was ¥7,289,911.33, a significant recovery from a loss of -¥202,651,117.19 in the same period last year, marking a 103.60% increase[9] Operating Costs and Expenses - The company reported a 37.78% reduction in operating costs, totaling ¥329,277,082.41 compared to ¥529,178,611.99 in the previous year[8] - Total operating costs for the current period are ¥622,063,638.81, down 25.4% from ¥834,140,687.01 in the previous period[18] - Research and development expenses decreased by 30.74% to ¥13,116,487.67 from ¥18,938,606.15 year-on-year[8] - Research and development expenses for the current period are ¥13,116,487.67, a decrease from ¥18,938,606.15 in the previous period[18] Shareholder Information - Total number of common stock shareholders at the end of the reporting period is 67,022[11] - The largest shareholder, Dunhua Jincheng Industrial Co., Ltd., holds 27.35% of shares, totaling 327,080,749 shares[11] - The total number of preferred stock shareholders at the end of the reporting period is not applicable[13] Other Information - The company has not disclosed any new product or technology developments in this reporting period[14] - There are no significant mergers or acquisitions reported during this period[14] - The company has not provided specific future outlook or performance guidance in the current report[14]

证券代码:000623 证券简称:吉林敖东 公告编号: 2025-026 吉林敖东药业集团股份有限公司 关于聘任公司副总经理的公告 特此公告。 附件：王超先生简历。 吉林敖东药业集团股份有限公司董事会 2025 年 4 月 30 日 1 吉林敖东药业集团股份有限公司（下称"公司"）于 2025 年 4 月 29 日召开 第十一届董事会第十七次会议，审议通过了《关于聘任王超先生为公司副总经理 的议案》。结合市场环境、医药行业发展以及公司发展阶段，根据《公司法》《公 司章程》等相关规定，经总经理郭淑芹提名，公司董事会提名委员会审查，公司 董事会研究决定聘任王超先生担任公司副总经理，由王超先生负责公司整体医药 产品的战略统筹、渠道精耕、产销协同、品牌重塑等工作。任期自董事会会议审 议通过之日起至第十一届董事会任期届满为止。 王超先生不存在《公司法》《深圳证券交易所股票上市规则》等法律法规及 《公司章程》规定禁止任职的情形。公司董事会聘任王超先生为公司副总经理的 程序符合法律、法规和《公司章程》的有关规定。 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记 载、误导性陈述或者重大遗漏。 附件：王超先生 ...

证券代码：000623 证券简称：吉林敖东 吉林敖东药业集团股份有限公司 投资者关系活动记录表 编号：2025-002 | | □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 | | | --- | --- | --- | | 投资者关系活 | | | | 动类别 | □新闻发布会 □路演活动 | | | | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称 | 通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | 及人员姓名 | 参与本次 2024 年度业绩说明会的投资者 | | | 时间 | 2025 年 4 28 日（星期一）15:00—17:00 | 月 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net） | | | | 采用网络远程的方式召开业绩说明会 | | | 上市公司接待 | 副董事长、总经理：郭淑芹 | | | | 独立董事：肖维维 | | | 人员姓名 | 董事、副总经理、财务总监：张淑媛 | | | | 董事、副总经理、董事会秘书：王振宇 | | | | 1、行业以后 ...

Core Viewpoint - Jilin Aodong Pharmaceutical Group Co., Ltd. reported a revenue of 2.611 billion yuan and a net profit of 1.551 billion yuan for 2024, with a debt-to-asset ratio of 11.27%, while actively adapting to changes in the pharmaceutical industry through a multi-driven development model of "pharmaceuticals + finance + health" [2][3] Group 1: Financial Performance - The company achieved a revenue of 2.611 billion yuan and a net profit attributable to shareholders of 1.551 billion yuan in 2024 [2] - The proposed cash dividend for 2024 is 3 yuan per 10 shares, totaling an estimated distribution of 352 million yuan, alongside a mid-year dividend of 239 million yuan, bringing the total cash dividends and share buybacks to 891 million yuan, which is 57.43% of the net profit [7] Group 2: Business Strategy - Jilin Aodong is focusing on building a competitive advantage across the entire pharmaceutical industry chain, including traditional Chinese medicine, chemical drugs, and health products, while enhancing its "pharmaceuticals + finance + health" multi-driven development model [3][4] - The company is implementing a marketing strategy centered on "big product groups + multiple product groups" to cultivate core products and strengthen channel management, aiming for a revenue of 2.274 billion yuan from its pharmaceutical segment [3][4] Group 3: Innovation and R&D - The company has established an innovative R&D system that integrates production, learning, and research, achieving significant results in the field of Chinese medicine formula granules [4][6] - Jilin Aodong is leveraging advanced research technologies and digital production to modernize and automate traditional Chinese medicine manufacturing, while also participating in the establishment of brand demonstration bases for Chinese medicinal materials [6][7]

Core Insights - The company reported a total revenue of 2.61 billion yuan in 2024, a decrease of 24.31% compared to 2023, which had a revenue of 3.45 billion yuan [1] - The pharmaceutical sector remains the main revenue driver, contributing 1.88 billion yuan, accounting for 72.11% of total revenue, despite a 27.83% decline from the previous year [1][3] - The company is focusing on key products in its traditional Chinese medicine segment, which includes core products like Anshen Bnna Liquid and Xiaor Chai Gui Oral Liquid, driving significant revenue [3] Revenue Breakdown by Sector - Pharmaceutical revenue: 1,882,395,047.83 yuan (72.11%), down 27.83% from 2,608,458,378.94 yuan [1] - Chain pharmacy wholesale and retail: 391,365,987.46 yuan (14.99%), up 4.36% from 375,020,113.62 yuan [1] - Other business income: 73,862,569.09 yuan (2.83%), up 62.06% from 45,577,260.70 yuan [1] Product Performance - Traditional Chinese medicine sales: 1,605,541,287.90 yuan (61.50%), down 25.42% from 2,152,662,657.59 yuan [1] - Chemical drugs revenue: 276,853,759.93 yuan (10.61%), down 39.26% from 455,795,721.35 yuan [1] - Health products sales reached 2.12 billion yuan, accounting for 8.13% of total revenue [4] Regional Performance - Northeast region: 968,305,996.09 yuan (37.09%), down 14.76% from 1,135,942,714.05 yuan [1] - North region: 377,546,862.16 yuan (14.46%), up 39.78% from 270,101,901.70 yuan [1] - South region: 330,176,089.26 yuan (12.65%), down 20.40% from 414,786,414.20 yuan [1] Sales Strategy and Growth - The company is enhancing its online sales through platforms like JD, Taobao, and Pinduoduo, while also implementing O2O business models in physical stores [4] - The chain pharmacy segment added 183,000 new members, bringing the total to 1.19 million members [3] - The company closed 11 stores and opened 17 new ones, ending the reporting period with a total of 190 stores [3]

Group 1 - Jilin Aodong (000623.SZ) reported its 2024 annual results on April 23, 2025, with 235 institutional investors holding a total of 414 million shares, representing 34.58% of the total share capital [1] - The top ten institutional investors collectively hold 31.95% of the shares, with a decrease of 6.05 percentage points compared to the previous quarter [1] Group 2 - In the public fund sector, one public fund increased its holdings, while eight funds decreased their holdings, with a reduction rate of 0.33% [2] - A total of 219 new public funds were disclosed this period, including several major ETFs [2] - One foreign fund, Hong Kong Central Clearing Limited, reduced its holdings by 0.31% compared to the previous quarter [2]

Core Viewpoint - The company, Jilin Aodong Pharmaceutical Group Co., Ltd., is positioned in the pharmaceutical manufacturing industry, focusing on traditional Chinese medicine and chemical drugs, and is adapting to market challenges while pursuing innovation and quality improvement in its product offerings [1][4][18]. Company Overview - Jilin Aodong was established in 1957 and has evolved into a publicly listed company with a diversified business model that includes pharmaceuticals, finance, and health [16][17]. - The company has a total asset value of 33.002 billion yuan and a net asset value of 29.282 billion yuan as of the end of 2024 [17]. Industry Characteristics - The pharmaceutical industry is characterized by high investment, high risk, and long R&D cycles, with a demand that is relatively inelastic and less affected by economic cycles [2][4]. - The global pharmaceutical market is projected to reach 1.64 trillion USD in 2024, driven by factors such as aging populations and the rise of chronic diseases [3]. Business Performance - In 2024, the pharmaceutical manufacturing industry in China reported stable revenue of 2.5289 trillion yuan, but profits decreased by 1.1% year-on-year to 342.07 billion yuan [4]. - Jilin Aodong's revenue from its three main business segments (traditional Chinese medicine, chemical drugs, and retail pharmacy) was 2.27376 billion yuan, a decrease of 23.79% compared to the previous year [19]. Product Portfolio - The company holds 627 production approval numbers, including 314 for traditional Chinese medicine and 313 for chemical drugs, with 211 products listed in the national medical insurance directory [20][18]. - Key products include "Anshen Bnnao Liquid," "Xiaoer Cha Gui Fever Oral Liquid," and "Xuefu Zhuyu Oral Liquid," which have established strong market positions [27][28][29]. R&D and Innovation - The company employs a dual approach of "independent innovation + open collaboration" in its R&D efforts, focusing on traditional Chinese medicine modernization and product quality enhancement [26]. - Jilin Aodong has been recognized for its innovative products and has received multiple awards for its contributions to the pharmaceutical industry [17][29]. Regulatory Environment - The company is adapting to regulatory changes, including the promotion of fair pricing for generic drugs and the enhancement of traditional Chinese medicine standards [5][8]. - Recent government initiatives aim to improve the quality and efficiency of medical services, which will impact the pharmaceutical sector positively [6][7]. Financial Health - The company has maintained a strong credit rating of AA+ and has successfully managed its debt obligations, including the repayment of convertible bonds [33][37]. - The company has also engaged in stock buybacks to enhance shareholder value, reducing its registered capital accordingly [39][40].

登录新浪财经APP 搜索【信披】查看更多考评等级 2．不触及其他风险警示情形的具体原因 4.深圳证券交易所要求的其他文件。 特此公告。 公司最近一个会计年度净利润为正值，且合并报表、母公司报表年度末未分配利润均为正值，2022- 2024年累计现金分红及回购注销总额2,366,583,519.48元，占最近三个会计年度平均净利润 1,597,358,031.67元的148.16%，最近三个会计年度累计现金分红金额不低于最近三个会计年度年均净利 润的30%。公司不触及《深圳证券交易所股票上市规则》第9.8.1条规定的可能被实施其他风险警示情 形。 3.现金分红方案合理性说明 公司2024年度现金分红方案已充分考虑所处行业特点、发展阶段、自身经营模式、盈利水平、偿债能 力、资本需求等因素，兼顾业务持续健康发展与股东综合回报。 公司2024年度利润分配预案符合中国证监会《上市公司监管指引第3号一一上市公司现金分红》等法律 法规、规范性文件、《公司章程》及《未来三年（2024年-2026年）股东回报规划》等规定和要求，该 利润分配预案综合考虑公司经营业绩、经营净现金流情况、未来经营发展和股东回报等因素，具备合法 性、 ...